GlassScriptPhysician profile
Javier Chiriboga
NPI 1811352669
$9,224.75
in general payments reported to CMS, 2019-2025
29 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,609 · 2022: $2,263 · 2023: $1,932 · 2024: $1,619 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,267.80 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,029.97 | 2021-2025 | Evenity, Prolia, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $828.45 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $792.32 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $670.87 | 2021-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $604.26 | 2022-2025 | |
| Abbvie INC. | $603.21 | 2021-2025 | |
| Pfizer INC. | $358.63 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $358.27 | 2021-2022 | |
| Radius Health, INC. | $303.15 | 2021-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $210.77 | 2024-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $156.56 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $147.77 | 2021 | |
| Glaxosmithkline, LLC. | $129.41 | 2023-2025 | Benlysta, Nucala |
| Scilex Pharmaceuticals INC. | $112.56 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $106.73 | 2022-2025 | Monovisc, Orthovisc |
| Lilly USA, LLC | $79.83 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $75.46 | 2022-2024 | Zilretta, Exparel, Iovera |
| Pacira Therapeutics, INC. | $73.41 | 2021 | |
| Genentech USA, INC. | $60.43 | 2023-2025 | Actemra |
| Sobi, INC | $45.80 | 2021-2025 | |
| Organon LLC | $40.80 | 2021-2024 | Renflexis, Hadlima |
| Bioventus LLC | $39.68 | 2022-2024 | Supartz Fx Sodium Hyaluronate |
| Aurinia Pharma U.S., INC. | $24.28 | 2025 | Lupkynis |
| Alvogen INC | $23.77 | 2025 | Teriparatide |
| Grt US Holding, INC. | $23.07 | 2022 | |
| Fresenius Kabi USA, LLC | $20.89 | 2025 | |
| Endo USA, INC. | $20.81 | 2025 | Xiaflex |
| Alexion Pharmaceuticals, INC. | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Chiriboga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.